Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder
Study Findings to be Featured Today at Brain Stimulation Conference Symposium
BURLINGTON, Mass. and JERUSALEM, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, announced the publication in the scientific journal Biological Psychiatry of a new randomized, placebo-controlled, double-blind clinical trial assessing the safety and efficacy of the Companys proprietary Deep TMS System for adults with alcohol use disorder (AUD). A presentation of the results of the study will be given today at the 4th International Brain Stimulation Conference in Charleston, South Carolina.
The pilot study analyzed data from 46 subjects and revealed encouraging efficacy data relative to placebo in adults with AUD. The primary endpoint of the trial was the reduction in percentage of heavy drinking days (pHDD) over the twelve-week period after the Deep TMS treatment. A heavy drinking day was defined as a day during which four or more drinks were consumed for women, or five or more drinks for men. Subjects in the active Deep TMS group had an average of 2.9 pHDD during the three-month follow-up period compared to 10.6 pHDD in the placebo, a clinically meaningful and statistically significant difference. The H7 Coil is designed to target the medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC), structures both associated with AUD.
We are excited about the results of this feasibility study of Deep TMS for patients suffering from alcohol use disorder, said Christopher Boyer, Vice President of Global Marketing for BrainsWay. Like many other mental health disorders, there have been a number of reports showing that the global pandemic has exacerbated the prevalence of the alcohol use disorder. With limited treatment options for this life-altering disorder, it is promising to see that Deep TMS therapy may have a meaningful role in addressing this serious worldwide health issue.
Story continues
Previous studies suggest that lowering alcohol consumption for several weeks among patients suffering from AUD can initiate recovery of executive and general cognitive functioning, as well as structural and functional modifications throughout the brain. As such, the reduction in consumption induced by active treatment suggests that Deep TMS may be a powerful tool in benefitting those suffering from AUD.
While we are gaining accumulating knowledge of brain circuits implicated in addictions, it is exciting to present these promising results achieved with Deep TMS in AUD patients said Prof. Abraham Zangen, Head of the Brain Stimulation and Behavior Lab and the Chair of the PsychoBiology Brain Program at Ben-Gurion University and a scientific consultant for and member of the board of directors of BrainsWay. This feasibility study, which also included brain imaging measures, is a first step in more fully understanding the potential benefits of Deep TMS for patients suffering from AUD.
Prof. Zangen will present the findings of the study, along with data on Deep TMS in other addictions including smoking addiction, as part of a featured symposium being held today on novel brain stimulation treatments at the Brain Stimulation Conference, a gathering of prominent researchers and global market leaders in the neuroscience space.
About the StudyThe randomized, controlled, double-blind study was conducted at Ben-Gurion University and the Soroka Medical Center, Beer Sheva, Israel. Data from 46 subjects who completed the acute phase of the treatment course out of 51 eligible subjects who were enrolled into the study and initiated treatment was analyzed. Participants were divided into two groups receiving either 20 sessions of Deep TMS with the H7 Coil or placebo stimulation over the course of three months, with five sessions per week during the first three weeks (acute treatment) and five maintenance sessions during the three months of follow-up. Results revealed that the reduction in the percent of heavy drinking days in the active Deep TMS group were significantly greater than that of the placebo group (p = 0.037). Likewise, the reduction in craving levels, a secondary outcome, was significantly greater in active participants versus sham (p = 0.01).
In addition, functional MRI performed before and after the acute treatment revealed that active stimulation modified the connectivity between the ACC and the mPFC as well as the caudate, which may indicate an increased ability to overcome alcohol cravings.
For both the active and placebo groups, treatments were administered following symptom provocation which was tailored to the subjects specific alcoholic beverage preferences. The primary endpoint was the difference between the groups in the pHDD reduction, as measured during the three-month follow-up period.
Additional evaluations included modifications to structural and functional brain imaging measures. Participants were active alcohol consumers who consumed alcohol in the past month but not in the five days prior to the first MRI scan and/or the first treatment Deep TMS treatment session. During the acute treatment phase, in which relapse to alcohol drinking was prohibited for safety reasons, urine samples were collected daily for alcohol biomarkers. During the follow-up phase, urine samples were collected only during the Deep TMS maintenance treatment visits. Consumption and craving were assessed using standard questionnaires.
The BrainsWay Deep TMS H7 Coil was used in the study and included a placebo element situated within the helmet to facilitate patient and provider blinding. The placebo element produces an acoustic artifact and scalp sensations similar to those achieved with active stimulation from the Deep TMS H7 Coil, albeit with a negligible induced electric field that is insufficient to lead to a therapeutic effect.
No serious adverse events or side effects were reported in the study.
About Alcohol Use Disorder (AUD)The most prevalent substance use disorder globally, alcohol use disorder (AUD) encompasses the collection of clinical conditions associated with an inability to cease or control alcohol consumption including alcohol abuse, alcohol dependence, alcohol addiction, and alcoholism. As of 2018, there were more than 280 million people worldwide with AUD, and in 2019, 14.1 million adults were living with AUD in the United States. Factors contributing to developing AUD include alcohol misuse (e.g., binge drinking and heavy drinking), drinking at an early age, genetics and family history, and mental health conditions such as depression and post-traumatic stress disorder. The economic burden of AUD in the US in 2010 was calculated at $249 billion per year.
About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit http://www.brainsway.com.
Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Moreover, the pilot data presented herein, including outcomes/results, patient safety information and adverse event data, remain subject to further analysis and may be subject to further modification. Certain results as expressed herein may be subject to further analysis, modification and/or statistical penalties. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Companys anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Companys intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications; continuation and/or exacerbation of the global supply chain crisis and its impact on the Companys ability to source components, meet customer demand, fill orders, maintain pricing levels and support the Companys service needs; and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
Contacts: BrainsWay:Scott AregladoSVP and Chief Financial Officer844-386-7001Scott.Areglado@BrainsWay.com
Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com
Media Contact:Will Johnsonbrainsway@antennagroup.com(201) 465-8019
Continued here:
- Despite currently being unprofitable, EDAP TMS (NASDAQ:EDAP) has delivered a 52% return to shareholders over 5 years - Simply Wall St - April 18th, 2024 [April 18th, 2024]
- BrainsWay Expands Deep TMS Access in Israel Following Significant Increase in Reimbursement Rates - GlobeNewswire - April 18th, 2024 [April 18th, 2024]
- Mastery Logistics Systems partners with Transflo to integrate Workflow AI with MasterMind TMS to deliver a ... - Business Wire - April 18th, 2024 [April 18th, 2024]
- New form of magnetic brain stimulation spells hope for patients with treatment-resistant depression - The Straits Times - April 18th, 2024 [April 18th, 2024]
- Port of Oakland's new TMS provides real-time insights for truckers - CCJ - February 5th, 2024 [February 5th, 2024]
- TMS Taps Michelson To Oversee Global Talent Development 01/02/2024 - MediaPost Communications - February 5th, 2024 [February 5th, 2024]
- 11.24% CAGR Growth in Transportation Management Systems (TMS) Market by Solution (on-premise and cloud-based ... - PR Newswire - February 5th, 2024 [February 5th, 2024]
- MileMaker announces partnership with Turvo to bring advanced TMS - TheTrucker.com - The Trucker - February 5th, 2024 [February 5th, 2024]
- Transportation Management Software & Solutions - Who are the Major Players in the Indian Market? - India Shipping News - February 5th, 2024 [February 5th, 2024]
- Neural effects of TMS trains on the human prefrontal cortex | Scientific Reports - Nature.com - December 25th, 2023 [December 25th, 2023]
- What to know about TMS and how it can treat mental health issues - News3LV - December 25th, 2023 [December 25th, 2023]
- Neuronetics lands FDA clearance for TMS therapy accessory - Medical Device Network - December 25th, 2023 [December 25th, 2023]
- Neurobiological mechanisms of ECT and TMS treatment in ... - BMC Psychiatry - October 31st, 2023 [October 31st, 2023]
- Mishimoto Partners with Redwood Logistics for Seamless TMS ... - Supply Chain Dive - October 31st, 2023 [October 31st, 2023]
- 3 benefits of integrating WMS and TMS software - TechTarget - October 31st, 2023 [October 31st, 2023]
- Trinium and BlueCargo join forces to increase resiliency and agility ... - American Journal of Transportation - October 31st, 2023 [October 31st, 2023]
- Psychiatrist Convicted of Billing Medicare and Private Insurance ... - Department of Justice - October 31st, 2023 [October 31st, 2023]
- FreightPOP TMS Application Earns Acumatica Certification - PR Web - October 31st, 2023 [October 31st, 2023]
- AML RightSource Offers Support for Transaction Monitoring System Selection and Integration - Global Banking And Finance Review - October 31st, 2023 [October 31st, 2023]
- TMS therapy: The cloud hanging over me was gone - WellSpan Health - May 18th, 2023 [May 18th, 2023]
- Depression Relief: Brain Signal Reversal by Magnetic Pulses - Neuroscience News - May 18th, 2023 [May 18th, 2023]
- HWS CENTER LAUNCHES TMS THERAPY, BRINGING CUTTING-EDGE MENTAL HEALTH TREATMENT TO NEW JERSEY - EIN News - May 18th, 2023 [May 18th, 2023]
- Incoming TMS students take tours of site - Yahoo News - May 18th, 2023 [May 18th, 2023]
- Passion Drives TMS Titanium's Todd Harrison - Drag Illustrated - May 18th, 2023 [May 18th, 2023]
- EDAP TMS S A : Positive results from two studies reconfirm safety ... - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Shiba Inu (SHIB) Whale Purchasing Into The TMS Network (TMSN ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- TMS Coils Market 2023 Business Growth and Opportunities with Top ... - Cottonwood Holladay Journal - May 18th, 2023 [May 18th, 2023]
- The Top Cryptos To Buy In 2023 - Arbitrum, Polygon and TMS Network - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- Accelerated delivery of transcranial magnetic stimulation is safe and effective - Newswise - May 18th, 2023 [May 18th, 2023]
- Polygon (MATIC) and Solana (SOL) Drop by 10%, While TMS ... - Crypto Reporter - May 18th, 2023 [May 18th, 2023]
- VeChain (VET) & Curve DAO Token (CRV) Investors Diversify Their ... - Analytics Insight - May 18th, 2023 [May 18th, 2023]
- As Cardano (ADA) Stumbles And Dogecoin (DOGE) Falters, TMS ... - UseTheBitcoin - May 18th, 2023 [May 18th, 2023]
- Nexstim's Quality System and NBS 6 Receive MDR - GlobeNewswire - May 18th, 2023 [May 18th, 2023]
- Uniswap (UNI) and Shiba Inu (SHIB) Underwater as Crypto Looks ... - The Merkle Hash - May 18th, 2023 [May 18th, 2023]
- NeuroStim TMS Celebrates Landmark Achievement, Delivering Over 100,000 TMS Treatments Upon Reaching Five Year Anniversary - Yahoo Finance - May 6th, 2023 [May 6th, 2023]
- Modeling the antidepressant treatment response to transcranial ... - Nature.com - May 6th, 2023 [May 6th, 2023]
- USD Coin (USDC) & Optimism (OP)'s Investors Are Aping Into TMS ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Presale Gains 2400%: Optimism (OP) and ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- The Best Anime By TMS Entertainment - GameRant - May 6th, 2023 [May 6th, 2023]
- TMS Network (TMSN) Predicted To Pass Shiba Inu (SHIB) And Stacks (STX) In Popularity Within A Year | - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Towering Over Solana (SOL) and Dogecoin (DOGE), TMS Network (TMSN) Takes the Crown | Bitcoinist.com - Bitcoinist - May 6th, 2023 [May 6th, 2023]
- Market Corrections Push Cardano (ADA) and Polygon (MATIC ... - Analytics Insight - May 6th, 2023 [May 6th, 2023]
- Chainlink vs TMS Network vs TRON : One of them With Deliver ... - The Coin Republic - May 6th, 2023 [May 6th, 2023]
- PCS Software Named a Preferred Partner as Kuebix TMS Sunsets - Benzinga - May 6th, 2023 [May 6th, 2023]
- Could Musk Suit Have Negative Impact on Dogecoin (DOGE) and ... - Crypto Reporter - May 6th, 2023 [May 6th, 2023]
- The Future of Logistics: How Technology is Revolutionizing the ... - Robotics and Automation News - May 6th, 2023 [May 6th, 2023]
- Baru Gold Designated "National Vital Object" and Updates ... - Junior Mining Network - May 6th, 2023 [May 6th, 2023]
- Early Bird offer for TMS Awards - The Maritime Standard - May 6th, 2023 [May 6th, 2023]
- St Helen's Hospital patient says many are 'devastated' by its imminent closure - ABC News - May 6th, 2023 [May 6th, 2023]
- Transcranial Magnetic Stimulation (TMS) | Sibley Memorial Hospital in ... - March 31st, 2023 [March 31st, 2023]
- Psychiatry | Sibley Memorial Hospital in Washington, D.C. - March 31st, 2023 [March 31st, 2023]
- Want To Win Big? Experts Suggest To Choose TMS Network (TMSN) Over Arbitrum (ARB) And Polygon (MATIC) | - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS Network (TMSN) AI Infrastructure Will Give You 100x Returns, Way Better Than SingularityNET (AGIX) And - Bitcoinist - March 31st, 2023 [March 31st, 2023]
- TMS: What It Felt Like for Me I Psych Central - February 20th, 2023 [February 20th, 2023]
- Are we in a recession? Crypto giant Bitcoin and Ethereum stall out while TMS Network makes its mark - FXStreet - February 20th, 2023 [February 20th, 2023]
- Are GameFi coins like SHIB and Decentraland (MANA) as good of a long term investment as TMS Network? - FXStreet - February 20th, 2023 [February 20th, 2023]
- Launch of New Tron (TRX)-powered AI on the Way, Doritos Launches Project on Polygon (MATIC) While TMS Network (TMSN) Brings New Hopes for Brighter... - February 20th, 2023 [February 20th, 2023]
- What is a Transportation Management System? | Oracle - January 31st, 2023 [January 31st, 2023]
- TMS (Transcranial Magnetic Stimulation): What It Is - January 19th, 2023 [January 19th, 2023]
- HC Wainwright Adjusts Price Target on EDAP TMS S.A to $12 From $11, Maintains Buy Rating - Marketscreener.com - November 21st, 2022 [November 21st, 2022]
- Breakthrough in brain stimulation offers cautious hope for depression - Harvard Health - October 21st, 2022 [October 21st, 2022]
- Life-changing treatment program in Ohio expanding for veterans and first responders - WTRF - October 19th, 2022 [October 19th, 2022]
- Over 60% Of Pokemon Fans Are Most Excited For This Feature In Scarlet & Violet - SVG - October 19th, 2022 [October 19th, 2022]
- Radaro and NorthStar Digital Solutions partner to solve industry-wide process gaps in LTL & TL transportation - PR Newswire - October 19th, 2022 [October 19th, 2022]
- Avalanche Technology and TMS-Elektronik Announce Representation Agreement for the Republic of Turkey - PR Web - October 17th, 2022 [October 17th, 2022]
- Global Talent Management Software (TMS) Market Report 2022: A $25+ Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunities and... - October 17th, 2022 [October 17th, 2022]
- A Foreword to Adam Smith's The Theory of Moral Sentiments - Independent Institute - October 17th, 2022 [October 17th, 2022]
- Deutsche Telekom to buy 100% electric company cars from 2023 - www.electrive.com - October 17th, 2022 [October 17th, 2022]
- What Happens in the Brain During Transcranial Magnetic Stimulation? - Technology Networks - October 13th, 2022 [October 13th, 2022]
- TMS and SIS to vie for soccer championship - Saipan Tribune - October 13th, 2022 [October 13th, 2022]
- Soterix Medical Announces award of Fast Track NIH grant to develop a Parcel-Guided software to improve efficacy of rTMS treatment for Depression - PR... - October 13th, 2022 [October 13th, 2022]
- Interview: Kindra Neely Talks Healing Through Art and Personal Hope in 'Numb to This' - The Mary Sue - October 13th, 2022 [October 13th, 2022]
- Local veteran finds success with TMS therapy | Local News | thenewsenterprise.com - Elizabethtown News Enterprise - September 29th, 2022 [September 29th, 2022]
- Racin' Today Everything's Big In Texas Including Criticism Of TMS - RacinToday.com - September 29th, 2022 [September 29th, 2022]
- Start over from scratch: Race weekend at TMS stirs up track reconfiguration rumors - The Dallas Morning News - September 29th, 2022 [September 29th, 2022]
- $28 Billion Transportation Management System Markets - Global Forecast to 2027: Increasing Demand for TMS to Tackle High Demand from e-Commerce -... - September 29th, 2022 [September 29th, 2022]
- EDAP TMS Hosting Urology Expert Panel and Live Focal One Technology Demonstration - GlobeNewswire - September 29th, 2022 [September 29th, 2022]
- Reddick prevails in wild race that sees record number of yellow flags at TMS - Denton Record Chronicle - September 29th, 2022 [September 29th, 2022]
- e2log and Wipro Discuss How Technology Accelerates Logistics Engines That Drive Global Supply Chains at Gartner Supply Chain Symposium/Xpo 2022 EMEA -... - September 29th, 2022 [September 29th, 2022]
- Transcranial Magnetic Stimulators Market Size And Forecast To 2022 |eNeura BrainsWay Ltd., MagVenture, Nexstim Plc, TMS Neuro Solutions, Magstim The... - September 29th, 2022 [September 29th, 2022]